Flawed Medicare drug law was product of massive industry lobbying campaign
The pharmaceutical and HMO industries blitzed Congress with 952 lobbyists and spent $141 million in 2003 to pass a Medicare drug benefit that protects industry price-gouging while providing only meager benefits to seniors, according to a new Public Citizen study. Nearly half of the lobbyists have "revolving door" connections to Congress, the White House or federal agencies.
|
